Short-Term Outcomes and Cost-Effectiveness between Long-Course Chemoradiation and Short-Course Radiotherapy for Locally Advanced Rectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Long-course chemoradiotherapy (LCRT) has been widely recommended in a majority of rectal cancer patients. Re cently, encouraging data on short-course radiotherapy (SCRT) for rectal cancer has emerged. In this study, we aimed to compare these two methods in terms of short-term outcomes and cost analysis under the Korean medical insurance system. Materials and Methods: Sixty-two patients with high-risk rectal cancer, who underwent either SCRT or LCRT followed by total mesorectal excision (TME), were classified into two groups. Twenty-seven patients received 5 Gy×5 with two cycles of XELOX (capecitabine 1000 mg/m2 and oxaliplatin 130 mg/m2 every 3 weeks) followed by TME (SCRT group). Thirty-five patients received capecitabine-based LCRT followed by TME (LCRT group). Short-term outcomes and cost estimation were assessed between the two groups. Results: Pathological complete response was achieved in 18.5% and 5.7% of patients in the SCRT and LCRT groups, respectively (p=0.223). The 2-year recurrence-free survival rate did not show significant difference between the two groups (SCRT vs. LCRT: 91.9% vs. 76.2%, p=0.394). The average total cost per patient for SCRT was 18% lower for inpatient treatment (SCRT vs. LCRT: $18787 vs. $22203, p<0.001) and 40% lower for outpatient treatment (SCRT vs. LCRT: $11955 vs. $19641, p<0.001) compared to LCRT. SCRT was shown to be the dominant treatment option with fewer recurrences and fewer complications at a lower cost. Conclusion: SCRT was well-tolerated and achieved favorable short-term outcomes. In addition, SCRT showed significant reduc tion in the total cost of care and distinguished cost-effectiveness compared to LCRT.
Abstract
Purpose: Long-course chemoradiotherapy (LCRT) has been widely recommended in a majority of rectal cancer patients. Re cently, encouraging data on short-course radiotherapy (SCRT) for rectal cancer has emerged. In this study, we aimed to compare these two methods in terms of short-term outcomes and cost analysis under the Korean medical insurance system. Materials and Methods: Sixty-two patients with high-risk rectal cancer, who underwent either SCRT or LCRT followed by total mesorectal excision (TME), were classified into two groups. Twenty-seven patients received 5 Gy×5 with two cycles of XELOX (capecitabine 1000 mg/m2 and oxaliplatin 130 mg/m2 every 3 weeks) followed by TME (SCRT group). Thirty-five patients received capecitabine-based LCRT followed by TME (LCRT group). Short-term outcomes and cost estimation were assessed between the two groups. Results: Pathological complete response was achieved in 18.5% and 5.7% of patients in the SCRT and LCRT groups, respectively (p=0.223). The 2-year recurrence-free survival rate did not show significant difference between the two groups (SCRT vs. LCRT: 91.9% vs. 76.2%, p=0.394). The average total cost per patient for SCRT was 18% lower for inpatient treatment (SCRT vs. LCRT: $18787 vs. $22203, p<0.001) and 40% lower for outpatient treatment (SCRT vs. LCRT: $11955 vs. $19641, p<0.001) compared to LCRT. SCRT was shown to be the dominant treatment option with fewer recurrences and fewer complications at a lower cost. Conclusion: SCRT was well-tolerated and achieved favorable short-term outcomes. In addition, SCRT showed significant reduc tion in the total cost of care and distinguished cost-effectiveness compared to LCRT.
참고문헌 (29)
- Kapiteijn E, "Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer", N Engl J Med, 345, pp.638~646 (2001)
- Sebag-Montefiore D, "Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer(MRC CR07 and NCIC-CTG C016) : a multicentre, randomised trial", Lancet, 373, pp.811~820 (2009)
- Sauer R, "Preoperative versus postoperative chemoradiotherapy for rectal cancer", N Engl J Med, 351, pp.1731~1740 (2004)
- Martling A, "The Stockholm II trial on preoperative radiotherapy in rectal carcinoma : long-term follow-up of a population-based study", Cancer, 92, pp.896~902 (2001)
- van Gijn W, "Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer : 12-year follow-up of the multicentre, randomised controlled TME trial", Lancet Oncol, 12, pp.575~582 (2011)
- Sauer R, "Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer : results of the German CAO", ARO, J Clin Oncol, pp.2012, 30[DOI]
- Erlandsson J, "Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer(Stockholm III) : a multicentre, randomised, non-blinded, phase 3, non-inferiority trial", Lancet Oncol, 18, pp.336~346 (2017)
- Bujko K, "Long-course oxaliplatin-based preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for cT4or fixed cT3 rectal cancer : results of a randomized phase III study", Ann Oncol, 27, pp.834~842 (2016)
- Fernandez-Martos C, "Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging : the GEMCAD 0801 phase II multicenter trial", Oncologist, 19, pp.1042~1043 (2014)
- Bahadoer RR, "Short-course radiotherapy followed by chemotherapy before total mesorectal excision(TME)versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer(RAPIDO) : a randomised, open-label, phase 3 trial", Lancet Oncol, 22, pp.29~42 (2021)
- Bujko K, "Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer", Br J Surg, 93, pp.1215~1223 (2006)
- Raldow AC, "Cost-effectiveness of short-course radiation therapy vs long-course chemoradiation for locally advanced rectal cancer", JAMA Netw Open, 2, pp.e192249~ (2019)
- Wang S, "Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer", Radiat Oncol, 14, pp.113~ (2019)
- Hanly P, "Direct costs of radiotherapy for rectal cancer : a microcosting study", BMC Health Serv Res, 15, pp.184~ (2015)
- Smith NJ, "Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer", Br J Surg, 95, pp.229~236 (2008)
- Kim NK, "Total mesorectal excision for rectal cancer with emphasis on pelvic autonomic nerve preservation : expert technical tips for robotic surgery", Surg Oncol, 24, pp.172~180 (2015)
- Nagtegaal ID, "Current concepts of colorectal cancer resection pathology", Histopathology, 66, pp.102~111 (2015)
- Washington MK, "Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum", Arch Pathol Lab Med, 133, pp.1539~1551 (2009)
- Mandard AM, "Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations", Cancer, 73, pp.2680~2686 (1994)
- Briggs AH, "Probabilistic analysis of cost-effectiveness models : choosing between treatment strategies for gastroesophageal reflux disease", Med Decis Making, 22, pp.290~308 (2002)
- O’Brien BJ, "In search of power and significance : issues in the design and analysis of stochastic cost-effectiveness studies in health care", Med Care, 32, pp.150~163 (1994)
- Black WC, "The CE plane : a graphic representation of cost-effectiveness", Med Decis Making, 10, pp.212~214 (1990)
- Swedish Rectal Cancer Trial, "Improved survival with preoperative radiotherapy in resectable rectal cancer", N Engl J Med, 336, pp.980~987 (1997)
- Ngan SY, "Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer : Trans-Tasman Radiation Oncology Group trial 01. 04", J Clin Oncol, 30, pp.3827~3833 (2012)
- Ciseł B, "Long-course preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer : long-term results of the randomized Polish II study", Ann Oncol, 30, pp.1298~1303 (2019)
- Chung MJ, "Preoperative short-vs. long-course chemoradiotherapy with delayed surgery for locally advanced rectal cancer", Oncotarget, 8, pp.60479~60486 (2017)
- Yeo SG, "Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer : a phase 2 multicenter study(KROG 10-01)", Int J Radiat Oncol Biol Phys, 86, pp.34~39 (2013)
- Francois Y, "Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphinctersparing surgery for rectal cancer : the Lyon R90-01 randomized trial", J Clin Oncol, 17, pp.2396~ (1999)
- Garcia-Aguilar J, "Optimal timing of surgery after chemoradiation for advanced rectal cancer : preliminary results of a multicenter, nonrandomized phase II prospective trial", Ann Surg, 254, pp.97~102 (2011)